Bill Cadwallder, senior commercialization officer with PATH, and Bruce Markham, president and CEO at Diapin Therapeutics, will be the featured speakers at this networking event. They’ll talk about how patient advocacy groups can potentially serve as a source of seed or clinical trial funding, especially for companies whose technology targets a specific disease. For details and registration, click here.